Companies › Lunan Better Pharmaceutical
2 active drug programs in 2 registered trials: 2 Phase 3; Respiratory, Ophthalmology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Formoterol Beta-2 adrenergic receptor agonist | ADRB2 | Phase 3 | Asthma (Diagnosis) | Jun 2028 |
| Lifitegrast Integrin alpha-L/beta-2 (LFA-1) antagonist | ITGAL, ITGB2 | Phase 3 | Dry Eye Disease (DED) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06879782 | Lifitegrast | Phase 3 | Dry Eye Disease (DED) | Ophthalmology | Mar 2026 |
| NCT07768891 | Formoterol | Phase 3 | Asthma (Diagnosis) | Respiratory | Jun 2028 |
Chiesi Farmaceutici AstraZeneca GSK Actimed Therapeutics ARS Pharmaceuticals Polarean Novartis EyeD Pharma Acer Therapeutics Teva Branded Pharmaceutical Products R&D
Santen SAS Tecnoquimicas Neurotech Pharmaceuticals Innostellar Biotherapeutics Oorja Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.